Associate Professor Adam Vorn Patterson
Adam Patterson obtained his BA (hons) in Biochemistry at the University of Oxford, UK, and his PhD in the field of Bioreductive prodrugs whilst jointly located at the Institute of Molecular Medicine, Oxford and the Medical Research Council Radiobiology Unit, Harwell, UK, (in the laboratories of Prof Adrian Harris and Prof Ian Stratford, respectively). He then completed a postdoctoral fellowship at the University of Manchester developing hypoxia dependent viral therapeutics before joining the Auckland Cancer Society Research Centre in 2000. Dr Patterson is Leader of the TRANSLATIONAL THERAPEUTICS TEAM. He is currently Principal Investigator of two HRC project grants, and is an Associates Investigator on other grants (HRC, Marsden Fund, AMRF, NIH, ERC). In addition A/Prof Patterson leads the Tumour Microenvironment Flagship of the Maurice Wilkins Centre for Molecular Biodiscovery (Principle Investigator).
A/Prof Patterson has a broad interest in the metabolism of bioreductive prodrugs and their application as antitumour agents, with particular emphasis on selective targeting of the tumour microenvironment. Examples include TH-4000, currently in Phase 2 clinical trials in Lung cancer and Head/Neck cancer. He is also interested in replicating biological agents as cancer therapeutics.
Research | Current
- Discovery and development of TH-4000, a hypoxia-selective tyrosine kinase inhibitor (TKI) curently in Phase 2 clincial trials for lung cancer and Head/Neck cancer in USA and Australia
- Discovery of additional hypoxia-selective TKI prodrugs
- Development of the hypoxia-selective analogues of the prodrug PR-104
- Development of the AKR1C3-activated analogues of the prodrug PR-104
- Identification of human oxidoreductases for prodrug metabolism
- Identification of bacterial nitroreductases for prodrug metabolism
- Development of Gene-Directed Enzyme Prodrug Therapy (GDEPT).
- Armed Oncolytic virotherapy (VDEPT)
- Clostridia Delivered enzyme-prodrug therapy (CDEPT)
Teaching | Current
Lecturer in MEDSCI 714
Principle Supervisor of:
Ms Alexandra Mowday (PhD candidate)
Mr Shevan Silva (PhD candidate)
Ms Victoria Jackson (PhD candidate)
Selected publications and creative works (Research Outputs)
- Gu, Y., Guise, C. P., Patel, K., Abbattista, M. R., Lie, J., Sun, X., ... Wilson, W. R. (2011). Reductive metabolism of the dinitrobenzamide mustard anticancer prodrug PR-104 in mice. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 67 (3), 543-555. 10.1007/s00280-010-1354-5
Other University of Auckland co-authors: Kevin Sun, William Wilson